Relative Bronchodilating Effects of Formoterol When Administered Via Symbicort Pressurized Metered-dose Inhaler (pMDI) or Oxis Turbuhaler

AstraZeneca175 enrolled

Overview

The purpose of this study is to compare the therapeutic effects of formoterol in Symbicort with formoterol in Oxis Turbuhaler for the treatment of adults with stable asthma.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

175

Conditions

Stable Asthma

Interventions

budesonide/formoterolDRUG

formoterolDRUG

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * At least 18 years of age * Diagnosis of asthma and baseline lung function tests as determined by the protocol * Required and received treatment with inhaled corticosteroids within timeframe and doses specified in the protocol Exclusion Criteria: * Severe asthma * Has required treatment with any non-inhaled corticosteroids within previous 4 weeks, has sensitivity to drugs specified in protocol or requires treatment with beta-blockers

Outcomes

Primary Outcomes

Average FEV1 during 12 hours

Time frame: Once a week for 5 weeks during treatment period

Secondary Outcomes

Urine levels of formoterol in 2 different formulations

Time frame: Once a week (12 hour urine collection) for 5 weeks during treatment period

Safety profiles of formoterol in 2 different formulations

Time frame: Once a week for 5 weeks during treatment period

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.